European Journal of Epidemiology

, Volume 19, Issue 6, pp 513–516

Challenges in the Search for an HIV Vaccine

  • Angelique A.C. Lemckert
  • Jaap Goudsmit
  • Dan h. Barouch

DOI: 10.1023/B:EJEP.0000032423.87658.68

Cite this article as:
Lemckert, A.A., Goudsmit, J. & Barouch, D.h. Eur J Epidemiol (2004) 19: 513. doi:10.1023/B:EJEP.0000032423.87658.68


Considerable progress has been made over the past several years in the development of an HIV vaccine. As a result, a growing number of vaccine modalities are being investigated in pre-clinical and phase I/II clinical trials. However, a number of major scientific challenges still remain. It is widely believed that the ideal vaccine should elicit both neutralizing antibodies and cytotoxic T lymphocytes (CTL) against diverse isolates of HIV, but the precise correlates of immunity have not been defined. Recombinant live vector-based vaccines and plasmid DNA vaccines have been shown to induce CTL, either alone or in combination, and these CTL-based vaccines have shown partial protective efficacy in nonhuman primates challenge studies. An immunogen that elicits broadly reactive neutralizing antibodies, however, has yet to be developed.

HIVImmune responseVaccine

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Angelique A.C. Lemckert
    • 1
  • Jaap Goudsmit
    • 2
  • Dan h. Barouch
    • 3
  1. 1.Crucell Holland BVLeidenThe Netherlands
  2. 2.Crucell Holland BVLeidenThe Netherlands
  3. 3.Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA